鶹ý

Cath Lab Recap: Stopping Late Thrombosis; AAA Repair; Spying on Afib

— Interventional cardiology news to note

MedpageToday

A sirolimus-coated stent featuring a luminal anti-CD34+ antibody layer to attract endothelial progenitor cells for better healing showed beyond day 9 of implantation through to 1 year, the REMEDEE registry study found.

Could the ? A team of researchers was able to make an educated (and correct) guess in one case based on the kind of meta-data available to the agency. The tell: record of a call to a cardiac monitoring device hotline.

Women got than from stress testing in a randomized investigation (P=0.028). Men, on the other hand, seemed to glean as much from either modality.

Patients with hypertrophic cardiomyopathy were after catheter ablation for atrial fibrillation as those without the cardiomyopathy, a meta-analysis found. These patients also needed more repeat procedures and antiarrhythmic drugs following intervention.

A system for endovascular repair of infrarenal abdominal aortic aneurysms (AAAs) had only a at 1 year in the EVAS FORWARD-IDE trial, which was "the lowest rate ever reported for an IDE study of an endovascular AAA device," according to a company release. And freedom from device-related reintervention came in at 96.6%.

The FDA warned of heart infections from the 3T by Sorin/LivaNova due to aerosolized M. chimaera, particularly for patients getting a heart valve or other cardiac prosthesis.

After surgical aortic valve replacement for severe aortic stenosis, persists for about 20% of patients despite LV mass regression and preserved LV ejection fraction and is tied to more adverse events, a hypothesis-generating study showed.

  • author['full_name']

    Nicole Lou is a reporter for 鶹ý, where she covers cardiology news and other developments in medicine.